Recently it has been shown that in primary anaplastic large-cell lymphoma, an aggressive CD30+ CTCL, tumor cells also express KIR3DL2 and can be the target of a potent anti-tumor activity in vitro, re-enforcing this marker as a therapeutic target for these patients (78). The gene discussed is KIR3DL2; the disease is neoplasm.